Home
Storia in 1 fonti
Capricor Therapeutics' Duchenne treatment is heading for an FDA rejection
Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.
Raccontata da
statnews.com
Timeline cronologica
- ·
Capricor’s Duchenne muscular dystrophy drug and the countless tiny decisions that can make or break a study
“Regulatory flexibility can be exercised in rare disease without sacrificing rigor,” writes Mindy Leffler, whose son has Duchenne muscular dystrophy.
- ·
Capricor Therapeutics' Duchenne treatment is heading for an FDA rejection
Capricor Therapeutics is trying to stave off FDA rejection of its cell therapy for Duchenne muscular dystrophy.